Emerging markets | Market commentary Why has the Turkish lira collapsed?

Loose fiscal policy, rampant inflation, high levels of unhedged US dollar borrowing by corporates and a fast-escalating diplomatic stand-off between Turkey and the US are some of the main reasons behind the recent collapse of the lira.

14 Aug 2018

In somewhat of a vicious circle, investor fears about the ability of Turkish corporates to service US dollar loans due to the weakening currency are placing further pressure on the Turkish lira just as rumors about the introduction of capital controls have also added to market stress.

But more than anything the disorderly market reaction of recent days reflects, in our view, investors' growing concerns about the likelihood that a sustainably credible plan to address these issues will emerge under a president that to-date has been dismissive of economic orthodoxy and the views of international investors.

Over the weekend President Erdogan added fuel to an already well-established fire with accusations of an international conspiracy against Turkey, further combative rhetoric towards the US and a diatribe against the 'evil' of higher interest rates. In short, precisely the opposite of what international investors wanted to hear.

How did Turkey get to this point?

The shift from a parliamentary democracy to what is now effectively an executive presidency in Turkey with few checks and balances accelerated last April in a constitutional referendum that abolished the role of prime minister, truncated parliament and gave Erdogan sweeping powers over the judiciary and the power to make law by decree.

Perhaps foreseeing where the economy was headed, Erdogan called early general elections in June where he won a narrow majority that brought those changes into force.

While Erdogan's hostility towards higher interest rates is nothing new, markets were previously prepared to at least partly dismiss it as somewhat co-incident to the country's overall economic policy. But it has become clear that Erdogan's hostility to interest rates is as much philosophical as it is economic and as Erdogan’s power has increased and the independence of the central bank has been questioned, investors can no longer ignore Erdogan's dismissal of orthodox policy so easily.

On the political front, simmering tensions between Turkey and the US have now resulted in trade sanctions at a time when Turkey can least afford them. While grievances between the two NATO allies stretch back more than a decade, the focus of the current argument centers on Turkey’s plan to acquire a missile defense system from Russia and on Turkey's arrest and imprisonment of an American pastor on charges of espionage relating to the alleged coup against Erdogan in 2016. The US refutes the charges. The refusal of Turkey to release the pastor despite strong diplomatic representations from the US has now resulted in specific action against two Turkish ministers that the US holds responsible for the pastor’s detainment – and a doubling of tariffs on Turkish steel and aluminum.

What can Turkey do?

In our view the greatest challenge in overcoming this crisis is investors' disquiet around a perceived lack of independence at the Turkish central bank. Those fears originated with Erdogan's promise to get more involved in monetary policy in the run up to the elections in late June, were exacerbated significantly by the appointment of Erdogan's son in-law to head Turkey's powerful new treasury and finance ministry in early July – and ultimately confirmed by the failure of the central bank to raise interest rates in its first post-election meeting on July 24 despite soaring inflation.

The scale of the Turkish lira sell-off reflects that investors believe that at least part of the issue is now structural rather than cyclical and that the situation cannot improve without a U-turn from Erdogan that looks some way away based on current rhetoric. From our perspective it is very hard to see how confidence in central bank independence can be restored swiftly and sustainably as things currently stand.

Given net liabilities of around USD 250bn, demand for US dollars to service and repay debt is unlikely to abate any time soon and there are significant repayments due in the coming months. This structural imbalance is also something that cannot be addressed overnight. The good news is that the sharp drop in the Turkish lira should provide at least some positive impact on Turkey's current account deficit, making Turkey's exports cheaper and overseas goods more expensive. But tighter fiscal policy to further slow imports would be the most obvious policy response in any other country.

The weakness of the currency is likely to see inflation in Turkey spike still higher given the oil price has risen more than fivefold in Turkish lira terms since early 2016. Turkey should, of course, hike interest rates immediately, tighten fiscal policy and set out a clear plan for how it intends to address the imbalances in its economy. But given Erdogan's open hostility towards economic orthodoxy, things may have to get significantly worse before such obvious measures are executed. The very basic measures announced on Monday morning, while welcome, have done little to calm investor fears at the time of writing.

We see three potential policy scenarios:

  1. Turkish policymakers fail to act with sufficient force to avoid a full blown balance of payments crisis that may eventually require the involvement of the IMF. This is where we are currently. There is a risk that the Turkish lira weakens still further if this remains the situation.
  2. Turkey does the bare minimum to avoid the current situation evolving still further into an even larger crisis. Against that backdrop the lira might stabilize in the short-term, but it is hard to see more than transient periods of Turkish lira strength or any meaningful reversal of recent lira weakness
  3. A meaningful and coordinated action involving the government and the central bank, with tangible policies. Given the negative sentiment embedded in current Turkish lira levels we believe that this would surprise investors and prompt a sharp rebound in the lira.

Are there implications for emerging market asset classes and wider risk assets?

It is hard to dissect the current crisis in Turkey as definitively economic or geopolitical. In emerging markets (EM), the two are often strongly connected. We believe that the impact on investor sentiment is likely to be greater than the impact on the global economy.

Our view is that while the episode is a sharp reminder of the idiosyncratic risks within the emerging market universe and is unlikely to be swiftly resolved, we do not currently ascribe a high probability to sustained wider EM contagion.

That said the recent bout of US strength will challenge EM economies like Turkey with large current account deficits and high exposure to US dollar funded liabilities. These economies and related assets will likely remain under pressure as global quantitative easing unwinds and the availability of cheap credit declines.

However, this also presents opportunities for more differentiation across EM. The market reaction and related selloff within EM has been highly correlated in 2018, and strong EM economies have sold off perhaps unfairly alongside weaker EM economies. As a result, we believe that, there is opportunity across EM given current valuations to cherry pick those economies less externally vulnerable.

More specifically, emerging market equities have fallen a little over recent days, but there has been no evidence of large scale panic selling and overall the MSCI Emerging Markets index remains in positive territory over the past month in local currency terms. At around 0.6% of the MSCI Emerging Markets Index, Turkey is a very small part of the overall EM equity universe. We continue to see long-term value in EM equities but accept that broader investor risk aversion and US dollar strength are likely to constrain upside in the short-term.

In EM hard currency debt, spreads over US treasuries have widened around 40bp over the past week to around 430bp – their highest level since April 2016. We see the Turkey situation as idiosyncratic and not reflective of a wholesale change in the risk profile of all EM debt. For investors prepared to accept high levels of volatility and to take a long-term view, we believe that these are potentially attractive levels.

In FX, the weakness in the Turkish lira and new sanctions against Russia by the US are triggering some contagion to broader EM currencies universe. While we don’t believe that the issues in Turkey will have a sustained impact on EM currencies, the risk of escalating trade tensions and anemic growth levels outside of the US could place further pressure on EM currencies in the short-term.

Our view is that the Turkish lira is extremely undervalued on fundamentals but that these fundamentals matter little in the short-term when Erdogan's rhetoric is combative and political. Nonetheless the Turkish lira may have the potential to rally sharply in the short-term if more decisive action is taken to address the imbalances in the Turkish economy – and if Turkey is able to resolve its stand-off with the US.

Outside of EM a number of European banks have significant exposure to Turkey. These include Spain's BBVA, Italy's UniCredito and France's BNP Paribas. Share prices in all three have dropped between 5% and 10% over recent days. In our view, the very low valuations of European banks and the poor performance of the sector overall year-to-date partly reflect investors' concerns about Turkish exposure. The euro has also weakened as a result of these factors. We remain moderately constructive on European equities on a longer-term time horizon but see the increased risk premium prompted by recent political developments as likely to constrain upside potential, particularly until more clarity emerges around the fiscal intentions of the new Italian government.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.